At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 159 enrolled
Drug / intervention
PF-04136309 +1 moredrug
Likely dose
PF-04136309 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-WEEK, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE 2, MULTICENTER STUDY OF PF-04136309 IN SUBJECTS WITH OSTEOARTHRITIC PAIN OF THE KNEE
In Brief
A Phase 2 clinical trial evaluating PF-04136309 and Placebo for Osteoarthritis, Knee. Completed, enrolled 159 participants across 22 sites in 2 countries.
Detailed Summary
To evaluate the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics in patients with osteoarthritic pain of the knee. The most painful knee joint will be identified as the index joint at screening, and this joint will be used for all pain assessments throughout the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesSouth Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartAug 2008
Primary CompletionNov 2008
TodayJul 2026
First PostedJun 3, 2008
Enrollment StartAug 5, 2008
Primary CompletionNov 27, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.1 years ago
Interventions
PF-04136309drug
125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
Placebodrug
Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.